{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:26:41Z","timestamp":1761744401839},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"DOI":"10.2146\/ajhp150876","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T07:45:41Z","timestamp":1482392741000},"page":"e9-e16","source":"Crossref","is-referenced-by-count":11,"title":["Optimizing colistin dosing: Is a loading dose necessary?"],"prefix":"10.1093","volume":"74","author":[{"given":"Lama H.","family":"Nazer","sequence":"first","affiliation":[{"name":"Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Anabtawi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103123347400_b1-07400e9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.00035-06","article-title":"Colistin methanesulfonate is an inactive prodrug of colstin against Pseudomonas aeruginosa","volume":"50","author":"Bergen","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b2-07400e9","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.47.4.1364-1370.2003","article-title":"Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography","volume":"47","author":"Li","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b3-07400e9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","article-title":"Colistin in the 21st century","volume":"22","author":"Nation","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b4-07400e9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40560-015-0072-9","article-title":"Colistin for lung infection: an update","volume":"3","author":"Gurjar","year":"2015","journal-title":"J Intensive Care"},{"key":"key\n\t\t\t\t2019041103123347400_b5-07400e9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/cit680","article-title":"Consistent global approach on reporting of colistin doses to promote safe and effective use","volume":"58","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b6-07400e9","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b7-07400e9","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b8-07400e9","unstructured":"Clinical and Laboratory Standards Institute. M100-S25: performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement (January2015). Available from www.clsi.org."},{"key":"key\n\t\t\t\t2019041103123347400_b9-07400e9","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Clinical break-points-bacteria (v 5.0). www.eucast.org\/clinical_breakpoints\/ (accessed 2016 May 28)."},{"key":"key\n\t\t\t\t2019041103123347400_b10-07400e9","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b11-07400e9","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b12-07400e9","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1128\/AAC.03508-14","article-title":"New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale","volume":"58","author":"Gr\u00e9goire","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b13-07400e9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b14-07400e9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/civ717","article-title":"Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective study","volume":"61","author":"Dalfino","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b15-07400e9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000442786","article-title":"Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series","volume":"61","author":"Trifi","year":"2016","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t2019041103123347400_b16-07400e9","article-title":"Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multi-drug resistant gram-negative pneumonia","author":"Elefritz","year":"2016","journal-title":"J Intensive Care Med"},{"key":"key\n\t\t\t\t2019041103123347400_b17-07400e9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/clpt.2011.48","article-title":"Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers","volume":"89","author":"Couet","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041103123347400_b18-07400e9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019041103123347400_b19-07400e9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","article-title":"Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis","volume":"45","author":"Roberts","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041103123347400_b20-07400e9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0034-1398390","article-title":"Colistin: how should it be dosed for the critically ill?","volume":"36","author":"Landersdorfer","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"key\n\t\t\t\t2019041103123347400_b21-07400e9","unstructured":"ClinicalTrials.gov. Efficacy and mortality of a loading dose of colistin in critically ill patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02117986?term=colistin+loading&rank=2 (accessed 2016 May 27)."},{"key":"key\n\t\t\t\t2019041103123347400_b22-07400e9","unstructured":"European Medicines Agency. Annex III: amendments to relevant sections of the summary of product characteristic and the package leaflets. www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Polymyxin_31\/WC500176332.pdf (accessed 2016 May 28)."},{"key":"key\n\t\t\t\t2019041103123347400_b23-07400e9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after iv colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041103123347400_b24-07400e9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multi-drug resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103123347400_b25-07400e9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/cis909","article-title":"Association between colistin dose and microbiological outcomes in patients with multi-drug resistant gram-negative bacteremia","volume":"56","author":"Vicari","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b26-07400e9","unstructured":"JHP Pharmaceuticals, LLC. Coly-Mycin M Parenteral (colistimethate for injection, USP) (January2013). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050108s030lbl.pdf (accessed 2016 May 28)."},{"key":"key\n\t\t\t\t2019041103123347400_b27-07400e9","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","article-title":"Task force on management and prevention of Acinetobacter baumannii infections in the ICU","volume":"41","author":"Garnacho-Montero","year":"2015","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t2019041103123347400_b28-07400e9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103123347400_b29-07400e9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.etap.2014.03.004","article-title":"Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model","volume":"37","author":"Ghlissi","year":"2014","journal-title":"Environ Toxicol Pharmacol"},{"key":"key\n\t\t\t\t2019041103123347400_b30-07400e9","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/AAC.00343-13","article-title":"How does colistin-induced nephropathy develop and can it be treated?","volume":"57","author":"Ozkan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b31-07400e9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jac\/dkr483","article-title":"Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics","volume":"67","author":"Yousef","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103123347400_b32-07400e9","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1128\/AAC.00280-15","article-title":"Effect of ascorbic acid on colistin-associated nephrotoxicity: a preliminary clinical study","volume":"59","author":"Sirijatuphat","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/1\/e9\/28336459\/ajhp00e9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T17:07:37Z","timestamp":1568653657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/1\/e9\/5102512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150876","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2017,1,1]]}}}